Astrazeneca

Astra says potential blockbuster reduced high blood pressure

Patients in a late-stage trial received one of two different doses of Baxdrostat or a placebo drug once a day, the drugmaker said

AstraZeneca Pharma, Themis Medicare, PG Electroplast, Shilpa Medicare in Focus | Stocks On Radar

Gujarat Themis Biosyn to merge with Themis Medicare. AstraZeneca Pharma to launch Breztri Aerosphere in January 2025 in India. Shilpa Medicare subsidiary receives certificate of suitability (CEP) from EDQM, for API, Octreotide. Shilpa Medicare subsidiary receives certificate of suitability (CEP) from EDQM, for API, Octreotide. PG Electroplast subsidiary signs definitive agreement with Spiro Mobility to manufacture electric vehicles of Spiro in India. Watch here for more details -

AstraZeneca Pharma shares slip 4% as investors rush to book profits

So far in trade, over 16 lakh shares exchanged hands in trade on the bourses, compared to the one-month daily traded average of 88,400 shares.

AstraZeneca to invest Rs 250 crore for GCC expansion in Chennai

TN industries minister TRB Rajaa said rapid absorption of office spaces in Chennai underscores the state’s position as the Knowledge Capital of India

Thrombosis with Thrombocytopenia Syndrome: What is TTS, rare side effect of AstraZeneca Covid vaccine?

British pharmaceutical giant AstraZeneca has acknowledged that its Covid vaccine can lead to a rare blood clotting condition known as Thrombosis with Thrombocytopenia Syndrome (TTS)

AstraZeneca acknowledges rare blood clot risk of Covid vaccine in court for first time

Formerly referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT), this extremely rare complication has been recognised as a possible side effect of the vaccine

Pharma stocks rally up to 8% to 52-week highs amid rise in fresh Covid cases

The pharma industry is one of the few defensive industries and investor interest in it is also rising, as concerns about COVID-19 gain momentum, said Aamar Deo Singh, Senior Vice President, Research, Angel One.

AstraZeneca to exit the manufacturing site in Bangalore 'in due course'

The company said that it will begin search for a buyer who can also act as a contract manufacturing organisation for the products currently manufactured in the site

AstraZeneca Pharma fall 3% despite healthy Q2 net profit, revenue growth

The stock slipped amid reports of the Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, facing a legal challenge the UK

Gainers & Losers: 10 stocks that moved the most on June 2

The benchmark indices snapped a two-day losing streak to end higher but for the week, the Sensex and the Nifty ended flat. About 2,121 shares advanced, 1,327 declined and 124 remained unchanged on June 2

AstraZeneca gets CDSCO nod for cancer drug

The approval for Tremelimumab in combination with Durvalumab is based on results from Phase III HIMALAYA clinical trial and is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), the drug firm said.

AstraZeneca’s lung cancer drug also approved to treat biliary tract cancer

More than 30,000 new cases of biliary tract cancers are reported in the country every year with 90 percent of them diagnosed in the advanced stage

AstraZeneca India gets approval to market anti-diabetes drug

Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalisations due to heart failure in adults with progressive chronic kidney disease, the drug firm said.

AstraZeneca looks to more than double new cancer drugs by 2030

The UK drugmaker has added seven new cancer medicines since 2014, after Chief Executive Officer Pascal Soriot made a risky bet on an oncology pipeline to revive growth and ward off a hostile takeover from Pfizer Inc.